Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 6c
May 13, 2020 7:06 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q1 EPS of ($0.81), $0.06 worse than the analyst estimate of ($0.75).
Despite these unprecedented times, the first quarter was a period of important progress for Fulcrum and the fundamentals of our business remain strong, said Robert J. Gould, Ph.D.,... More
